Passage Bio Sets Nov 5 Vote on Remix Merger; Net Cash Estimate Rises to $10.9M
PASG is trading near its 52-week low of $3.29 (15% above the low).
Summary
Passage Bio's fourth S-4 amendment sets a November 5, 2026 vote on the Remix reverse merger and updates the anticipated net cash at closing to $10.9 million, up from the $5.0 million assumption used in the exchange ratio formula.
Key Events · M&A and Partnerships · PASG
-
Special Meeting Set for November 5, 2026
Passage Bio stockholders will vote on the Remix reverse merger at a virtual special meeting on November 5, 2026. Record date is September 30, 2026, with 3,217,810 shares outstanding and entitled to vote.
-
Net Cash Estimate Rises to $10.9M
The filing updates anticipated Passage Bio Net Cash at closing to approximately $10.9 million, up from the $5.0 million assumption used in the exchange ratio formula. This increases Passage Bio's valuation in the merger formula, slightly improving the ownership percentage for existing holders.
-
Ownership Split Unchanged: 6% / 65% / 29%
Post-merger ownership remains highly dilutive for Passage Bio holders: Remix pre-closing equityholders expected to own 65%, Passage Bio equityholders 6%, and concurrent financing investors 29% of the combined company.
-
Stock Price Near Nasdaq Minimum
Passage Bio stock closed at $4.12 on October 2, 2026, just above the $4.00 minimum bid price required for Nasdaq listing of the combined company. The proposed 1-for-2 to 1-for-10 reverse stock split is designed to maintain compliance.
Analysis · PASG · Life Sciences
Amendment No. 4 to the S-4 confirms the November 5, 2026 special meeting date and updates the anticipated Passage Bio Net Cash at closing to $10.9 million, up from the $5.0 million assumption used in the exchange ratio formula. The higher net cash balance increases Passage Bio's valuation in the merger formula, which would slightly improve the ownership percentage for existing Passage Bio stockholders relative to earlier estimates. The filing also sets the record date of September 30, 2026 with 3,217,810 shares outstanding, and notes the stock closed at $4.12 on October 2, 2026 — just above the $4.00 minimum bid price required for Nasdaq listing of the combined company. The merger remains highly dilutive for Passage Bio holders, who are expected to own only 6% of the combined company, with Remix holders at 65% and concurrent financing investors at 29%.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PASG was trading at $3.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.2M. The 52-week trading range was $3.29 to $20.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.